You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Article info

Article menu

Download PDFPDF

XML
Research Article
Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Authors

  • Xiang-Min Tong Department of HematologyZhejiang Provincial People’s Hospital, Hangzhou Medical College Hangzhou China PubMed articlesGoogle scholar articles
  • Liang Feng Cancer Biology Research CenterTexas Tech University Health Sciences Center School of Pharmacy Amarillo TX USA PubMed articlesGoogle scholar articles
  • Sreedhar Reddy Suthe Department of Pharmaceutical SciencesTexas Tech University Health Sciences Center School of Pharmacy Amarillo TX USA PubMed articlesGoogle scholar articles
  • Tian-Hao Weng State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China National Clinical Research Center for Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China PubMed articlesGoogle scholar articles
  • Chen-Yu Hu State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China National Clinical Research Center for Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China PubMed articlesGoogle scholar articles
  • Yi-Zhi Liu State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China National Clinical Research Center for Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China PubMed articlesGoogle scholar articles
  • Zhi-Gang Wu State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China National Clinical Research Center for Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China PubMed articlesGoogle scholar articles
  • Ming-Hai Wang Department of HematologyZhejiang Provincial People’s Hospital, Hangzhou Medical College Hangzhou China Cancer Biology Research CenterTexas Tech University Health Sciences Center School of Pharmacy Amarillo TX USA Department of Pharmaceutical SciencesTexas Tech University Health Sciences Center School of Pharmacy Amarillo TX USA State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China PubMed articlesGoogle scholar articles
  • Hang-Ping Yao State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China National Clinical Research Center for Infectious Diseases, First Affiliated HospitalZhejiang University School of Medicine Hangzhou China PubMed articlesGoogle scholar articles

Citation

Tong X, Feng L, Suthe SR, et al
Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
Journal for ImmunoTherapy of Cancer 2019;7:250. doi: 10.1186/s40425-019-0732-8
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.